Yun Shen1,2, Jian Zhou1,2, Lizheng Shi3, Elizabeth Nauman4, Peter T Katzmarzyk1, Eboni G Price-Haywood5, Ronald Horswell1, San Chu1, Shengping Yang1, Alessandra N Bazzano6, Somesh Nigam6, Gang Hu1. 1. Pennington Biomedical Research Centre, Baton Rouge, Louisiana. 2. Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. 3. Department of Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana. 4. Louisiana Public Health Institute, New Orleans, Louisiana. 5. Ochsner Health System Center for Outcomes and Health Services Research, New Orleans, Louisiana. 6. Blue Cross and Blue Shield of Louisiana, Baton Rouge, Louisiana.
Abstract
AIM: To compare the cardiovascular risks between users and non-users of sodium-glucose co-transporter-2 (SGLT2) inhibitors based on electronic medical record data from a large integrated healthcare system in South Louisiana. MATERIALS AND METHODS: Demographic, anthropometric, laboratory and medication prescription information for patients with type 2 diabetes who were new users of SGLT2 inhibitors, either as initial treatments or as add-on treatments, were obtained from electronic health records. Mediation analysis was performed to evaluate the association of use of SGLT2 inhibitors and changes of metabolic risk factors with the risk of incident ischaemic heart disease. RESULTS: A total of 5338 new users of SGLT2 inhibitors were matched with 13 821 non-users. During a mean follow-up of 3.26 years, 2302 incident cases of ischaemic heart disease were defined. After adjusting for multiple confounding factors, patients using SGLT2 inhibitors had a lower risk of incident ischaemic heart disease compared to patients not using SGLT2 inhibitors (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.54-0.73). Patients using SGLT2 inhibitors also had a lower risk of incident ischaemic heart disease within 6 months (HR 0.36, 95% CI 0.25-0.44), 12 months (HR 0.40, 95% CI 0.32-0.49), 24 months (HR 0.53, 95% CI 0.43-0.60) and 36 months (HR 0.65, 95% CI 0.54-0.73), respectively. Reductions in systolic blood pressure partly mediated lowering risk of ischaemic heart disease among patients using SGLT2 inhibitors. CONCLUSIONS: The real-world data in the present study show the contribution of SGLT2 inhibitors to reducing risk of ischaemic heart disease, and their benefits beyond glucose-lowering.
AIM: To compare the cardiovascular risks between users and non-users of sodium-glucose co-transporter-2 (SGLT2) inhibitors based on electronic medical record data from a large integrated healthcare system in South Louisiana. MATERIALS AND METHODS: Demographic, anthropometric, laboratory and medication prescription information for patients with type 2 diabetes who were new users of SGLT2 inhibitors, either as initial treatments or as add-on treatments, were obtained from electronic health records. Mediation analysis was performed to evaluate the association of use of SGLT2 inhibitors and changes of metabolic risk factors with the risk of incident ischaemic heart disease. RESULTS: A total of 5338 new users of SGLT2 inhibitors were matched with 13 821 non-users. During a mean follow-up of 3.26 years, 2302 incident cases of ischaemic heart disease were defined. After adjusting for multiple confounding factors, patients using SGLT2 inhibitors had a lower risk of incident ischaemic heart disease compared to patients not using SGLT2 inhibitors (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.54-0.73). Patients using SGLT2 inhibitors also had a lower risk of incident ischaemic heart disease within 6 months (HR 0.36, 95% CI 0.25-0.44), 12 months (HR 0.40, 95% CI 0.32-0.49), 24 months (HR 0.53, 95% CI 0.43-0.60) and 36 months (HR 0.65, 95% CI 0.54-0.73), respectively. Reductions in systolic blood pressure partly mediated lowering risk of ischaemic heart disease among patients using SGLT2 inhibitors. CONCLUSIONS: The real-world data in the present study show the contribution of SGLT2 inhibitors to reducing risk of ischaemic heart disease, and their benefits beyond glucose-lowering.
Authors: William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: Stroke Date: 2019-02 Impact factor: 7.914
Authors: Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Ping Yin; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: J Diabetes Date: 2018-11-13 Impact factor: 4.006
Authors: Shannon M Dunlay; Michael M Givertz; David Aguilar; Larry A Allen; Michael Chan; Akshay S Desai; Anita Deswal; Victoria Vaughan Dickson; Mikhail N Kosiborod; Carolyn L Lekavich; Rozalina G McCoy; Robert J Mentz; Ileana L Piña Journal: Circulation Date: 2019-06-06 Impact factor: 29.690
Authors: Silvio E Inzucchi; Bernard Zinman; Christoph Wanner; Roberto Ferrari; David Fitchett; Stefan Hantel; Rosa-Maria Espadero; Hans-Jürgen Woerle; Uli C Broedl; Odd Erik Johansen Journal: Diab Vasc Dis Res Date: 2015-01-14 Impact factor: 3.291
Authors: Frederik Persson; Thomas Nyström; Marit E Jørgensen; Bendix Carstensen; Hanne L Gulseth; Marcus Thuresson; Peter Fenici; David Nathanson; Jan W Eriksson; Anna Norhammar; Johan Bodegard; Kåre I Birkeland Journal: Diabetes Obes Metab Date: 2017-09-08 Impact factor: 6.577
Authors: Xiaoyun Yang; Qian Liu; Yuxin Fan; Li Ding; Ruodan Wang; Gang Hu; Ming Liu Journal: Front Endocrinol (Lausanne) Date: 2021-07-22 Impact factor: 5.555